Kolexia
Roblin Xavier Gastro-entérologie
Roblin Xavier
Gastro-entérologie
Hôpital Nord CHU Saint-Étienne - Loire
Saint-Priest-en-Jarez, France
409 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Maladies inflammatoires intestinales Maladie de Crohn Rectocolite hémorragique Colite Ulcère Nécrose Infections à cytomégalovirus Inflammation Tumeurs colorectales

Collaborateurs

Voir plus
Peyrin-Biroulet Laurent
Peyrin-Biroulet Laurent
Hôpital Brabois, Vandoeuvre-lès-Nancy, France
Nancey Stephane
Nancey Stephane
Hôpital Lyon Sud, Pierre-Bénite, France
Laharie David
Laharie David
Hôpital Haut-lévêque, Pessac, France
Fumery Mathurin
Fumery Mathurin
Centre Hospitalier D'Amiens Salouël Site Sud, Salouël, France

Industries

Voir plus
Abbvie
106 collaboration(s)
Dernière en 2023
Janssen
77 collaboration(s)
Dernière en 2023
Takeda Pharmaceutical
68 collaboration(s)
Dernière en 2023
Edimark
30 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
RECIDREAM: Evaluation of Sleep Changes as Early Markers of Relapse in Patients With Inflammatory Bowel Diseases (IBD).
Essai Clinique (Hospices Civils de Lyon)   18 mars 2024
LUCENT-URGE: A Multicenter, Phase 3b, Open-Label, Single-Arm Study to Investigate Bowel Urgency and Its Relationship With Other Outcome Measures in Adults With Moderately to Severely Active Ulcerative Colitis Treated With Mirikizumab
Essai Clinique (Lilly)   07 mars 2024
A Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease
Essai Clinique (Celgene)   06 mars 2024
VEDIAN: Comparison of Vedolizumab Treatment to Adalimumab Dose Intensification in Crohn's Disease Patients With Loss of Response or Biomarker Activity to Adalimumab on First Line With Therapeutic Drug Concentration: A Randomized, Multicentre, Controlled Trial
Essai Clinique (Takeda Pharmaceutical)   05 mars 2024
VERDICT: In actiVE Ulcerative Colitis, a RanDomIzed Controlled Trial for Determination of the Optimal Treatment Target
Essai Clinique (Takeda Pharmaceutical)   20 février 2024
Physical Activity and IBD: State of Art and Knowledge, Patients and Healthcare Professionals Points of View, A French Multicenter Cross Sectional Study.
Inflammatory bowel diseases   08 février 2024
USTAP: USTekinumab in Fistulising Perianal Crohn's Disease (CD): The USTAP CD Study
Essai Clinique (Janssen)   18 janvier 2024
TRENCH 1: TRansmural hEaliNg Definition in CroHn's Disease - The TRENCH1 Study
Essai Clinique (Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives)   15 janvier 2024
ABTECT - Maintenance: A Randomized, Double-blind, Multicenter Phase III Study to Evaluate the Long-term Efficacy and Safety of ABX464 25 mg or 50 mg Once Daily as a Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis
Essai Clinique (Abivax S.A.)   15 décembre 2023
ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1: A Randomized, Double-blind, Placebo-controlled, Multicenter Phase III Study to Evaluate the Efficacy and Safety of ABX464 Once Daily for Induction Treatment in Subjects With Moderately to Severely Active Ulcerative Colitis
Essai Clinique (Abivax S.A.)   15 décembre 2023